-
Empire Asset Assigns Penny Stock Lipocine $21 Price Target, Buy Rating
Tuesday, February 27, 2018 - 12:45pm | 369Read More...Lipocine Inc (NASDAQ: LPCN) is still down 57 percent since the U.S. Food and Drug Administration’s Bone, Reproductive and Urologic Drugs Advisory Committee voted 6-13 on Tlando’s benefit-risk profile. But one Street analyst is not only undeterred but is encouraged by the drug’s...
-
Empire Analyst Sees 200% Upside To This Women's Health Biotech
Thursday, February 22, 2018 - 4:03pm | 295Read More...Viveve Medical Inc (NASDAQ: VIVE) is rapidly expanding — its sales force, its treatment indications, its revenue and its fan base, according to a bullish analyst. The Rating Empire Asset Management Company’s Dr. Cathy Reese initiated coverage on Viveve Medical with a Buy rating...
-
Empire Slaps $4 Target On Exact Sciences
Friday, February 26, 2016 - 9:40am | 251Read More...Empire Asset Management’s Dr. Cathy Reese maintained a Sell rating on EXACT Sciences Corporation (NASDAQ: EXAS), while revising the price target to $4. Exact Sciences reported 4Q15 revenues of $14.4 million and a net loss of about $40 million which was higher than the year ago net loss...
